Correction to: British Journal of Cancer (2017) 117, 1495–1506; https://doi.org/10.1038/bjc.2017.317; published online 14 September 2017
The original version of this article contained an error in Fig. 6A. The volumes of the tumour xenografts were incorrectly calculated. The correct figure and figure legend are below, where the volume has been calculated using V = length × width2 × π/6. The interpretation of the data and conclusions are not affected.
CPT sensitized HCC xenografts to EPI treatment. Nude mice were injected with SMMC-7721 cells. CPT, Camptothecin; EPI, epirubicin. Mice were treated with CPT, EPI or in combination (COM) twice a week for a total of three times. At the end of the experiments, tumours were excised and weighed at the end of the experiment. a Tumour growth curves for SMMC-7721 xenografts. b Representative images of excised tumours. c Excised xenograft tumours weights at the end of the experiment. n = 8–10; *p < 0.05 vs. Veh control. #p < 0.05 vs EPI
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Chen, F., Wang, H., Zhu, J. et al. Correction: Camptothecin suppresses NRF2–ARE activity and sensitises hepatocellular carcinoma cells to anticancer drugs. Br J Cancer 121, 511–512 (2019). https://doi.org/10.1038/s41416-019-0527-1
Published:
Issue date:
DOI: https://doi.org/10.1038/s41416-019-0527-1
